Participant flow and recruitment.
8-dose
For the 4-year (8-dose) intervention, mean coverage for azithromycin and placebo was 83.2% ± 16.4% and 86.6% ± 12.0%, respectively. One village in the azithromycin arm withdrew from the trial after the 24-month time point (final village sample A total of 202 nasopharyngeal swabs in the azithromycin treatment group and 221 swabs in the placebo group were cultured for the 36-month time point (details for swab collection for 12 and 24 months are reported in reference 